Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: BMS is a global pharmaceutical and healthcare company. The reporting period covers the three and six months ended June 30, 2005. The company operates in three reportable segments: Pharmaceuticals, Nutritionals, and Related Healthcare. The Oncology Therapeutics Network (OTN) business was sold in May 2005 and is reported as discontinued operations.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2005 | Six Months Ended June 30, 2005 |
|---|---|---|
| Net Sales | $4,889 | $9,421 |
| Net Earnings (Continuing Ops) | $991 | $1,529 |
| Net Earnings (Total) | $1,004 | $1,537 |
| Diluted EPS (Continuing Ops) | $0.50 | $0.78 |
| Operating Cash Flow | N/A | $760 |
| Working Capital | $2,725 | N/A |
| Total Debt (Short + Long Term) | $6,300 | N/A |
| Cash & Cash Equivalents | $1,798 | N/A |
Note: Total Debt calculated as Short-term borrowings ($292M) + Long-term debt ($6,008M) as of June 30, 2005.
Material Changes vs. Prior Period
- Revenue: Net sales for the three months ended June 30, 2005, increased 1% to $4.889 billion compared to $4.819 billion in 2004. For the six months, sales were flat at $9.421 billion versus $9.445 billion in 2004. Growth was driven by volume and foreign exchange, offset by price decreases.
- Profitability: Net earnings from continuing operations surged 89% in the quarter to $991 million (from $523 million in 2004) and increased 3% for the six months to $1.529 billion. The quarterly increase was significantly aided by a lower effective tax rate (-1.9% vs 15.3%) and reduced litigation charges.
- Expenses: Litigation charges were a net benefit of $26 million in Q2 2005 (due to insurance recoveries) compared to a $379 million charge in Q2 2004. Research and development expenses increased 4% to $649 million in Q2 2005.
- Debt Reduction: Long-term debt decreased significantly from $8.463 billion (Dec 31, 2004) to $6.008 billion (June 30, 2005) following the repurchase of $2.5 billion in notes due in 2006.
Guidance, Outlook, and Risks
- Exclusivity Losses: Management expects substantial revenue losses in 2005, 2006, and 2007 due to patent expirations. For 2005, estimated net sales reductions range from $1.4 billion to $1.5 billion compared to 2004 levels, affecting products like PARAPLATIN, PRAVACHOL, and GLUCOPHAGE.
- Legal Proceedings: The company faces significant litigation risks, particularly regarding PLAVIX* patent infringement suits (Apotex, Dr. Reddy's, Teva). An adverse outcome could lead to generic competition before 2011. Additionally, the company is subject to ongoing investigations regarding wholesaler inventory and accounting practices, resulting in a Deferred Prosecution Agreement with the U.S. Attorney's Office.
- Divestitures: In July 2005, BMS agreed to sell its U.S. and Canadian Consumer Medicines business to Novartis AG for $660 million, expected to generate a pre-tax gain of $560 million to $600 million.
- Outlook: Management anticipates earnings growth will resume in 2007, supported by new product launches and the stabilization of the portfolio after exclusivity losses.
Investor Verification Checklist
- PLAVIX* Litigation Status: Verify the progress of patent infringement lawsuits in the U.S. and Canada, as a loss could materially impact future revenue streams.
- Deferred Prosecution Agreement (DPA): Review compliance with the DPA terms regarding inventory management and financial reporting controls.
- Consumer Medicines Sale: Confirm the closing date and final gain recognition for the sale of the Consumer Medicines business to Novartis.
- Product Exclusivity Timeline: Monitor the actual sales decline of PRAVACHOL and other products losing exclusivity in 2005-2006 against management's estimates.
- Insurance Recoveries: Assess the sustainability of litigation results, noting that Q2 2005 earnings were boosted by $295 million in insurance recoveries.